{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:13:27Z","timestamp":1773098007893,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brincidofovir (BCV) is a novel nucleoside phosphonate analogue with unique dual antiviral and anti-tumor properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The activity of BCV was evaluated in 44 cell-line models, including T\/NK-cell non-Hodgkin lymphoma (T\/NK-NHL,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925) and B-cell lymphoma (BCL,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919), and their respective NOD\/SCID mice xenograft models. The potential immunogenic effects were examined in a syngeneic EL4-C57BL\/6 murine lymphoma model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BCV demonstrated potent anti-tumor activity across the majority of cell lines regardless of EBV positivity, with IC50 values within clinically achievable human plasma concentrations (2 \u00b5g\/ml) in 17 of 25 (68.0%) T\/NK-NHL and in 13 of 19 (68.4%) BCL. In vivo treatment significantly inhibited tumor growth in all xenograft models compared to vehicle control. Notably, RNAseq analysis demonstrated BCV downregulated MYC-target pathways in T\/NK-NHL models. BCV evoked S-phase cell cycle arrest, replication stress, DNA damage, and apoptosis while triggering STING pathway-mediated interferon responses, PD-L1 expression, and immunogenic cell death. In the EL4-C57BL\/6 model, BCV in combination with anti-PD1 significantly inhibited tumor growth and triggered an immune reaction characterized by the highest scores for adaptive immune response, cytokines\/chemokines and receptors, cytotoxic cells, dendritic cells, NK CD56dim cells, and neutrophils (NanoString Immunology Panel).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Taken together, these results demonstrate a novel role for BCV in lymphoma therapy and suggest potential for combination with checkpoint immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04680-8","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:09:32Z","timestamp":1770354572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical activity of brincidofovir in peripheral T-cell and NK\/T-cell lymphoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Jason Yongsheng","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Chun Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelila Xin Ye","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boon Yee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing Yi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bavani","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui Yi","family":"Tay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tun Kiat","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Sook-Ting","family":"Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kah Suan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Ayuni Binte Muhammad","family":"Taib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dachuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing Quan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Hazama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin Tean","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Thye","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon Kiat","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"4680_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102793","volume":"129","author":"OA O'Connor","year":"2024","unstructured":"O\u2019Connor OA, Ma H, Chan JYS, Kim SJ, Yoon SE, Kim WS. Peripheral T-cell lymphoma: from biology to practice to the future. Cancer Treat Rev. 2024;129:102793.","journal-title":"Cancer Treat Rev"},{"key":"4680_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01560-7","volume":"17","author":"EWY Chang","year":"2024","unstructured":"Chang EWY, Tan YH, Chan JY. Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral T-cell lymphoma. J Hematol Oncol. 2024;17:38.","journal-title":"J Hematol Oncol"},{"key":"4680_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1068662","volume":"14","author":"DRY Yap","year":"2023","unstructured":"Yap DRY, Lim JQ, Huang D, Ong CK, Chan JY. Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer\/T-cell lymphoma. Front Immunol. 2023;14:1068662.","journal-title":"Front Immunol"},{"key":"4680_CR4","first-page":"384","volume":"58","author":"J Neyts","year":"1998","unstructured":"Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res. 1998;58:384\u20138.","journal-title":"Cancer Res"},{"key":"4680_CR5","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1038\/sj.onc.1206402","volume":"22","author":"B Abdulkarim","year":"2003","unstructured":"Abdulkarim B, Sabri S, Zelenika D, Deutsch E, Frascogna V, Klijanienko J, et al. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene. 2003;22:2260\u201371.","journal-title":"Oncogene"},{"key":"4680_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/jmv.21165","volume":"80","author":"T Yoshizaki","year":"2008","unstructured":"Yoshizaki T, Wakisaka N, Kondo S, Murono S, Shimizu Y, Nakashima M, et al. Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J Med Virol. 2008;80:879\u201382.","journal-title":"J Med Virol"},{"key":"4680_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/sj.leu.2403646","volume":"19","author":"M Luppi","year":"2005","unstructured":"Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia. 2005;19:473\u20136.","journal-title":"Leukemia"},{"key":"4680_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-6-18","volume":"6","author":"T De Schutter","year":"2013","unstructured":"De Schutter T, Andrei G, Topalis D, Naesens L, Snoeck R. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med Genomics. 2013;6:18.","journal-title":"BMC Med Genomics"},{"key":"4680_CR9","doi-asserted-by":"publisher","first-page":"47302","DOI":"10.18632\/oncotarget.10100","volume":"7","author":"B Mertens","year":"2016","unstructured":"Mertens B, Nogueira T, Stranska R, Naesens L, Andrei G, Snoeck R. Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms. Oncotarget. 2016;7:47302\u201318.","journal-title":"Oncotarget"},{"key":"4680_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070919","volume":"11","author":"F Verhees","year":"2019","unstructured":"Verhees F, Legemaate D, Demers I, Jacobs R, Haakma WE, Rousch M, et al. The antiviral agent cidofovir induces DNA damage and mitotic catastrophe in HPV-positive and -negative head and neck squamous cell carcinomas in vitro. Cancers (Basel). 2019;11:919.","journal-title":"Cancers (Basel)"},{"key":"4680_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113356","volume":"23","author":"ECY Lee","year":"2022","unstructured":"Lee ECY, Kok JST, Teh BT, Lim KS. Interplay between the DNA damage response and immunotherapy response in cancer. Int J Mol Sci. 2022;23:13356.","journal-title":"Int J Mol Sci"},{"key":"4680_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/fmb-2019-0288","volume":"15","author":"JJ Alvarez-Cardona","year":"2020","unstructured":"Alvarez-Cardona JJ, Whited LK, Chemaly RF. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. Future Microbiol. 2020;15:389\u2013400.","journal-title":"Future Microbiol"},{"key":"4680_CR13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1177\/10600280231151751","volume":"57","author":"J Huston","year":"2023","unstructured":"Huston J, Curtis S, Egelund EF. Brincidofovir: a novel agent for the treatment of smallpox. Ann Pharmacother. 2023;57:1198\u2013206.","journal-title":"Ann Pharmacother"},{"key":"4680_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00413-1","volume":"8","author":"DYX Ng","year":"2022","unstructured":"Ng DYX, Li Z, Lee E, Kok JST, Lee JY, Koh J, et al. Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor. NPJ Breast Cancer. 2022;8:44.","journal-title":"NPJ Breast Cancer"},{"key":"4680_CR15","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573-87.e29.","journal-title":"Cell"},{"key":"4680_CR16","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. <article-title update=\"added\">IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"issue":"5","key":"4680_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13577-025-01264-1","volume":"38","author":"KXY Chai","year":"2025","unstructured":"Chai KXY, Lee ECY, Li Z, Muhammad NAB, Lim JQ, Huang D, et al. Establishment and characterization of a novel patient-derived TP63-rearranged anaplastic large-cell lymphoma model PTCL-S1. Hum Cell. 2025;38:135.","journal-title":"Hum Cell"},{"key":"4680_CR18","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105:13520\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4680_CR19","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313\u201323.","journal-title":"N Engl J Med"},{"key":"4680_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1046\/j.1365-2133.2000.03769.x","volume":"143","author":"P Redondo","year":"2000","unstructured":"Redondo P, Idoate M, Galofr\u00e9 JC, Solano T. Cidofovir inhibits growth of B16 melanoma cells in vivo. Br J Dermatol. 2000;143:741\u20138.","journal-title":"Br J Dermatol"},{"key":"4680_CR21","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1158\/1078-0432.CCR-13-1121","volume":"19","author":"P Hadaczek","year":"2013","unstructured":"Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013;19:6473\u201383.","journal-title":"Clin Cancer Res"},{"key":"4680_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1124\/mol.106.026559","volume":"71","author":"S Liekens","year":"2007","unstructured":"Liekens S, Gijsbers S, Vanstreels E, Daelemans D, De Clercq E, Hatse S. The nucleotide analog cidofovir suppresses basic fibroblast growth factor (FGF2) expression and signaling and induces apoptosis in FGF2-overexpressing endothelial cells. Mol Pharmacol. 2007;71:695\u2013703.","journal-title":"Mol Pharmacol"},{"key":"4680_CR23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19:1189\u2013201.","journal-title":"Cell Rep"},{"key":"4680_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361.","journal-title":"Nat Med"},{"key":"4680_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood-2004-10-3906","volume":"106","author":"C Semino","year":"2005","unstructured":"Semino C, Angelini G, Poggi A, Rubartelli A. NK\/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 2005;106:609\u201316.","journal-title":"Blood"},{"key":"4680_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.immuni.2008.05.013","volume":"29","author":"H Kazama","year":"2008","unstructured":"Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity. 2008;29:21\u201332.","journal-title":"Immunity"},{"key":"4680_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1010639","volume":"10","author":"G Yu","year":"2022","unstructured":"Yu G, Chen Y, Hu Y, Zhou Y, Ding X, Zhou X. Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulation. Front Cell Dev Biol. 2022;10:1010639.","journal-title":"Front Cell Dev Biol"},{"key":"4680_CR28","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1158\/0008-5472.CAN-08-0085","volume":"68","author":"MF Fraga","year":"2008","unstructured":"Fraga MF, Berdasco M, Ballestar E, Ropero S, Lopez-Nieva P, Lopez-Serra L, et al. Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies. Cancer Res. 2008;68:4116\u201322.","journal-title":"Cancer Res"},{"key":"4680_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.leukres.2018.09.010","volume":"74","author":"MS Brassesco","year":"2018","unstructured":"Brassesco MS, Pezuk JA, Cortez MA, Bezerra Salom\u00e3o K, Scrideli CA, Tone LG. TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia. Leuk Res. 2018;74:42\u20136.","journal-title":"Leuk Res"},{"key":"4680_CR30","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.31557\/APJCP.2021.22.5.1653","volume":"22","author":"S Aref","year":"2021","unstructured":"Aref S, El-Ghonemy MS, Atia DM, Elbaiomy MM, Abdelsalam SA, Tawfik A, et al. Prognostic value of TLE1 gene expression in patients with T-cell acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2021;22:1653\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4680_CR31","unstructured":"Center for Drug Evaluation and Researchhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214460Orig1s000,%20214461Orig1s000ClinPharmR.pdf. Accessed 28 November 2025"},{"key":"4680_CR32","doi-asserted-by":"crossref","unstructured":"Grimley M, Maron G, Gomez CA, Prasad VK, Dara J, Papanicolaou GA, et al. Preliminary results of a phase 2a clinical trial to evaluate safety, tolerability and antiviral activity of intravenous brincidofovir (BCV IV) in immunocompromised patients with adenovirus infection. Blood. 202;142:112.","DOI":"10.1182\/blood-2023-179901"},{"key":"4680_CR33","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.jtct.2023.12.144","volume":"30","author":"M Grimley","year":"2024","unstructured":"Grimley M, Mar\u00f3n GM, Gomez CA, Prasad VK, Dara J, Lion T, et al. Preliminary results of a phase 2a clinical trial to evaluate safety, tolerability and antiviral activity of intravenous brincidofovir (BCV IV) in immunocompromised patients with adenovirus infection. Transplant Cell Ther. 2024;30:S89.","journal-title":"Transplant Cell Ther"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04680-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04680-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04680-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:45:42Z","timestamp":1773060342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04680-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4680"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04680-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tissue collection and consent protocols were under ethics approval by the SingHealth Centralized Institutional Review Board (CIRB 2018\/3084). Written informed consent from patients for the use of clinical data and biospecimens was obtained in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work is supported in part by funding from SymBio Pharmaceuticals Limited to J.Y.C. and C.K.O.; M.H. and K.F. are employees of SymBio Pharmaceuticals Limited. The remaining authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}